CTIS2022-502038-23-00招募中1 期
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controlled, investigator-initiated trial - The REC1TE trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Type 1 diabetes for more than five years according to World Health Organization criteria, Age 18–80 years, HbA1c < 80 mmol/mol, Stable insulin therapy (defined as no change in insulin brand and not newly initiated continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) therapy) and, if applicable, stable usage of glucose monitoring technology (e.g., continuous glucose monitoring CGM or intermittently scanned CGM) = 3 months with either MDI or CSII, C-reactive protein = 2 mg/l (measured by high-sensitivity assay), Estimated glomerular filtration rate > 50 ml/min/l/1.73 m^2, Either stable atherosclerotic cardiovascular (CV) disease (as defined by ischaemic heart disease including previous acute myocardial infarction, acute coronary syndrome and coronary revascularization; other arterial revascularization procedures; stroke and transient ischaemic attack; aortic aneurysm; peripheral arterial disease, including carotid atherosclerosis) or high risk thereof ((i.e., high or very high CV risk) as defined by the European Society of Cardiology (Eur Heart J 2020; 41: 255–323) or 10-year CV risk = 20 % (i.e., high CV risk) as according to ‘Steno Type 1 Diabetes Risk Engine’ (https://steno.shinyapps.io/T1RiskEngine/)
排除标准
- •Hypoglycemia unawareness (inability to register low blood glucose) am modum Pedersen-Bjergaard, unless usage of CGM with alarm function, On permanent treatment with colchicine that is not discontinued within 30 days of visit 0, Known or suspected hypersensitivity to colchicine, Liver disease with elevated plasma alanine aminotransferase (ALT) > three times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within seven days , and the last measured value as being conclusive), Receipt of any investigational drug within 30 days prior to visit 0, Simultaneous participation in any other clinical intervention trial, History of cirrhosis, chronic active hepatitis or severe hepatic disease, Inflammatory bowel disease or chronic diarrhea, Pre-existing progressive neuromuscular disease or persons with creatinine kinase levels > three times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive), Cancer or lymphoproliferative disease unless in complete remission for > 5 years, Immunosuppressive therapy or state of chronic immunodeficiency, including infection with human immunodeficiency virus (HIV), Thrombocyte count < 110 X 10^9/L, Blood dyscrasias (e.g., myelodysplastic syndromes or related hematological disorders), Leukocyte cell count < 3.0 X 10^9/L, Intake of grape fruit juice during trial participation, Systemic (oral or intravenous), long-term steroid therapy (topical or inhaled steroids are allowed), Hemodialysis or peritoneal dialysis therapy (since colchicine cannot be removed by dialysis or exchange transfusion), Renal or hepatic impairment treated with a P-gp inhibitor or a strong CYP3A4 inhibitor, Other concomitant disease or treatment that according to the investigator's assessment makes the person unsuitable for study participation, Alcohol/drug abuse, Fertile women not using chemical (tablet/pill, depot injection of progesterone, subdermal gestagen implantation, hormonal vaginal ring or transdermal hormonal patch) or mechanical (spirals) contraceptives, Pregnant or nursing women
研究者
相似试验
进行中（未招募）
2 期
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 DiabetesCardiovascular DiseasesChronic InflammationType 1 DiabetesNCT05949281Asger Lund, MD102
招募中
4 期
The effect of repurposing low-dose colchicine in older populations on platelet activation and inflammation (CO-OPERATE): A pilot trial.ACTRN12622000585729Concord Hospital Cardiology Department60
已完成
2 期
? The effect of Colchicine in preventing post pericardiotomy syndromepost pericardiotomy syndrome.Pericarditis in diseases classified elsewhereIRCT20141209020258N70Arak University of Medical Sciences120
尚未招募
2 期
Effect of Colchicine on secondary prevention of ischemic strokeIschemic stroke..IRCT20130311012781N5Ahvaz University of Medical Sciences20
尚未招募
4 期
The CO-POC trialCOlchicine for the prevention of Peri-Operative Complications: A prospective randomised placebo controlled, double blinded study to assess the role of colchicine in decreasing myocardial injury during cardiac surgeryMyocardial injuryCoronary artery bypass surgeryPost-pericardiotomy syndromePost-operative atrial fibrillationPost-operative effusionsACTRN12617000203358Sydney Local Health District204